Xenothera
Develops glyco-humanized antibody treatments for patients with a range of therapeutic needs
Highlights
- New on EvolcAdded 2026-10-30
About Xenothera
Xenothera develops glyco-humanized polyclonal antibodies using its antibody platform. Its therapeutic pipeline includes treatments in development for oncology and other indications.
The company is based in Nantes, France, and was founded in 2014. Its leadership includes a chairman and founder, a chief medical officer, a chief financial officer, a chief production officer and a chief strategic officer.
Product: Glyco-humanized polyclonal antibody treatments and a technology platform for developing them.
Jobs at Xenothera
No open positions listed right now.
Leadership
- Odile Duvaux · Chairman and founder; Chief Executive OfficerSource: company website
- Adrien Meynard · Chief Financial OfficerSource: company website
More biotech & pharma companies
Zymoptiq
Enzyme activity testing products and analytical services for industrial and research customersNew on Evolc4P-Pharma
Clinical-stage biotech developing drug candidates for serious diseases with unmet medical needsNew on EvolcAb Science
Develops pharmaceutical compounds for clinical programs in neurology, inflammatory diseases, oncology and viral diseasesNew on EvolcAbbelight
Super-resolution microscopy platform, sample-prep reagents and analysis software for biology researchers and biotech labsNew on EvolcAbivax
Develops obefazimod and other therapeutics for patients with chronic inflammatory diseasesNew on EvolcActicor Biotech
Clinical-stage biopharma developing glenzocimab, an antithrombotic antibody fragment for acute ischemic stroke patientsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Bootstrap
- Cookiebot
- Elementor
- PHP
- WordPress
- jQuery